Cognition Therapeutics, Inc.
NASDAQ:CGTXBiotechnology
-$0.01 today
- Market cap
- $57.06M
- Beta
- 1.75
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$0.22
Volume 0.34M
Average 1.23M
CGTX Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Cognition Therapeutics, Inc.NASDAQ: CGTX
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue falls 79.4% from a year ago
Deferred revenue stood at $220K at the end of Q1 FY2026, down 79.4% from a year earlier and down 40.1% from the prior quarter. Over 3 fiscal years it compounded at -40.0% a year.
Context
- Deferred revenue amounted to 0.6% of total assets at the end of Q1 FY2026, down 3.9 pp from a year earlier.
- Deferred revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -79.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 367K USD
- Year-over-year change
- -65.6%
- 4-year CAGR
- -16.4%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 367K | -65.6% |
| FY2024 | 2024-12-31 | 1.07M | -37.3% |
| FY2023 | 2023-12-31 | 1.7M | -0.1% |
| FY2022 | 2022-12-31 | 1.7M | +126.0% |
| FY2021 | 2021-12-31 | 753K | — |
Deferred Revenue vs competitors
How CGTX compares with its peers on the latest reported figures
- CGTX's Mar 2026 deferred revenue of $220K is the 2nd highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of -79.4% is the 2nd highest of 4, against a peer median of -100.0%.
- Deferred revenue amounts to 0.6% of total assets for CGTX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $334K | -19.1% | +36.9% | 0.1% | |
| Mar 2026 | $220K | -79.4% | -40.0% | 0.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | -54.7% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -70.8% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CGTX) | $0 | -100.0% | -54.7% | 0.0% | |
Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.72M | 41.56M | 29.92M | 25.01M | 36.81M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.27M | 3.67M | 1.28M | 2.69M | 9.92M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 11K | 0 | 3.02M | 0 | 1.26M |
| Total Current Assets | 58.99M | 47.65M | 34.22M | 29.56M | 47.99M |
| Property, Plant & Equipment (Net) | 145K | 1.05M | 941K | 679K | 399K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 1.73M | 0 | 0 | 0 |
| Total Non-current Assets | 145K | 2.78M | 941K | 679K | 399K |
| Total Assets | 59.14M | 50.43M | 35.16M | 30.23M | 48.39M |
| Account Payables | 4.17M | 3.22M | 3.7M | 1.98M | 1.12M |
| Short-term Debt | 0 | 634K | 544K | 279K | 307K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 753K | 1.7M | 1.7M | 1.07M | 367K |
| Other Current Liabilities | 2.48M | 870K | 1.17M | 1.53M | 1.57M |
| Total Current Liabilities | 7.86M | 7.8M | 10.17M | 11.14M | 13.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | (695K) | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 1.69M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 695K | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 2.38M | 520K | 342K | 195K |
| Total Liabilities | 7.86M | 10.18M | 10.69M | 11.48M | 14.12M |
| Common Stock | 22K | 29K | 32K | 60K | 90K |
| Retained Earnings | (94M) | (115.4M) | (141.19M) | (175.16M) | (198.65M) |
| Accumulated OCI | (198K) | (199K) | (195K) | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 51.27M | 40.25M | 24.47M | 18.75M | 34.27M |
| Total Debt | 0 | 1.48M | 1.24M | 814K | 638K |
| Net Debt | (54.72M) | (40.08M) | (28.68M) | (24.2M) | (36.17M) |
Cognition Therapeutics, Inc.
NASDAQ:CGTX
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.